GO
Loading...

Eli Lilly and Co

More

  • Final Glance: Pharmaceuticals companies Thursday, 18 Sep 2014 | 6:04 PM ET

    Baxter International Inc. rose$. 45 or. 6 percent, to $73.10. Bristol-Myers Squibb Co. rose$. 24 or. 5 percent, to $51.12. Hospira rose$. 07 or. 1 percent, to $53.51.

  • FDA approves Eli Lilly's injectable diabetes drug Thursday, 18 Sep 2014 | 4:41 PM ET

    WASHINGTON— The Food and Drug Administration has approved a new injectable diabetes drug from Eli Lilly and Co. for adults with the most common form of the disease.

  • Midday Glance: Pharmaceuticals companies Thursday, 18 Sep 2014 | 1:18 PM ET

    Baxter International Inc. rose$. 36 or. 5 percent, to $73.01. Bristol-Myers Squibb Co. rose$. 32 or. 6 percent, to $51.20. Hospira rose$. 24 or. 4 percent, to $53.68.

  • Final Glance: Pharmaceuticals companies Wednesday, 17 Sep 2014 | 6:04 PM ET

    Baxter International Inc. fell $2.34 or 3.1 percent, to $72.65. Bristol-Myers Squibb Co. fell$. 27 or. 5 percent, to $50.88. Hospira rose$. 19 or. 4 percent, to $53.44.

  • Sept 17- Testosterone replacement therapies should be reserved for men with specific medical conditions that impair function of the testicles, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday. The FDA is not obliged to follow the advice of its advisory panels but typically does so.

  • Experts want restrictions on testosterone drug use Wednesday, 17 Sep 2014 | 3:59 PM ET

    The labeling change would drastically limit the drugs' FDA- approved indication to men who have abnormally low hormone levels due to disease or injury, instead of aging. For years companies like AbbVie and Eli Lilly have linked the condition to a variety of ailments in common in aging men, including sexual dysfunction and low mood.

  • Midday Glance: Pharmaceuticals companies Wednesday, 17 Sep 2014 | 1:17 PM ET

    Baxter International Inc. fell $2.17 or 2.9 percent, to $72.82. Johnson& Johnson rose$. 01 or percent, to $105.89. Eli Lilly& Co. rose$. 01 or percent, to $65.81.

  • Early Glance: Pharmaceuticals companies Wednesday, 17 Sep 2014 | 10:29 AM ET

    Baxter International Inc. fell $1.33 or 1.8 percent, to $73.66. Bristol-Myers Squibb Co. fell$. 16 or. 3 percent, to $50.99. Hospira rose$. 09 or. 2 percent, to $53.34.

  • For Roche CEO, celebrating failure is key to success Wednesday, 17 Sep 2014 | 8:06 AM ET

    LONDON, Sept 17- Roche Chief Executive Severin Schwan likes to crack open the champagne with his drug research teams at the end of a big project- especially when they fail.

  • Final Glance: Pharmaceuticals companies Tuesday, 16 Sep 2014 | 7:46 PM ET

    Baxter International Inc. rose$. 44 or. 6 percent, to $74.99. Bristol-Myers Squibb Co. rose $1.20 or 2.4 percent, to $51.15. Hospira rose$. 46 or. 9 percent, to $53.25.

  • Midday Glance: Pharmaceuticals companies Tuesday, 16 Sep 2014 | 1:22 PM ET

    Baxter International Inc. rose$. 40 or. 5 percent, to $74.95. Bristol-Myers Squibb Co. rose$. 74 or 1.5 percent, to $50.69. Hospira rose$. 30 or. 6 percent, to $53.09.

  • Early Glance: Pharmaceuticals companies Tuesday, 16 Sep 2014 | 10:43 AM ET

    Baxter International Inc. rose$. 25 or. 3 percent, to $74.80. Bristol-Myers Squibb Co. rose$. 16 or. 3 percent, to $50.11. Hospira rose$. 01 or percent, to $52.80.

  • Lilly, AstraZeneca team up on Alzheimer's drug Tuesday, 16 Sep 2014 | 10:36 AM ET

    INDIANAPOLIS— Eli Lilly and Co. plans to pay up to $500 million to fellow drugmaker AstraZeneca as part of a collaboration to develop and sell a potential Alzheimer's disease treatment that is in the early stages of clinical testing.

  • NEW YORK, Sept 16- U.S. stocks were set to open lower on Tuesday with traders positioning for a Federal Reserve meeting expected to provide clues on the short term direction of U.S. interest rates.

  • US STOCKS-Futures dip ahead of data, Fed eyed Tuesday, 16 Sep 2014 | 7:33 AM ET

    *The Labor Department's producer price index, due at 8:30 a.m. EDT, is expected to have risen 0.1 percent in August, the same as in July.

  • *Lilly to partner on AstraZeneca's BACE inhibitor drug. LONDON, Sept 16- AstraZeneca has signed a partnership deal with U.S. rival Eli Lilly that could earn the British company up to $500 million if a promising- but risky- experimental Alzheimer's drug proves successful.

  • Final Glance: Pharmaceuticals companies Monday, 15 Sep 2014 | 6:03 PM ET

    Baxter International Inc. fell$. 15 or. 2 percent, to $74.55. Bristol-Myers Squibb Co. fell$. 31 or. 6 percent, to $49.95. Hospira rose$. 16 or. 3 percent, to $52.79.

  • Midday Glance: Pharmaceuticals companies Monday, 15 Sep 2014 | 1:24 PM ET

    Baxter International Inc. fell$. 31 or. 4 percent, to $74.39. Bristol-Myers Squibb Co. fell$. 32 or. 6 percent, to $49.95. Hospira rose$. 18 or. 3 percent, to $52.81.

  • Early Glance: Pharmaceuticals companies Monday, 15 Sep 2014 | 10:37 AM ET

    Baxter International Inc. fell$. 40 or. 5 percent, to $74.30. Bristol-Myers Squibb Co. fell$. 27 or. 5 percent, to $49.99. Johnson& Johnson fell$. 05 or percent, to $104.53.

  • Final Glance: Pharmaceuticals companies Friday, 12 Sep 2014 | 6:02 PM ET

    Baxter International Inc. fell$. 39 or. 5 percent, to $74.70. Bristol-Myers Squibb Co. fell$. 42 or. 8 percent, to $50.26. Hospira fell$. 36 or. 7 percent, to $52.63.